Novavax (NVAX) Operating Leases: 2020-2024
- Novavax's Operating Leases fell 9.25% to $76.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.7 million, marking a year-over-year decrease of 9.25%. This contributed to the annual value of $76.7 million for FY2024, which is 9.25% down from last year.
- According to the latest figures from Q4 2024, Novavax's Operating Leases is $76.7 million, which was down 9.25% from $84.5 million recorded in Q4 2023.
- Novavax's Operating Leases' 5-year high stood at $84.5 million during Q4 2023, with a 5-year trough of $39.1 million in Q4 2021.
- Moreover, its 3-year median value for Operating Leases was $81.3 million (2022), whereas its average is $80.8 million.
- Per our database at Business Quant, Novavax's Operating Leases fell by 22.09% in 2021 and then spiked by 107.90% in 2022.
- Novavax's Operating Leases (Quarterly) stood at $50.2 million in 2020, then decreased by 22.09% to $39.1 million in 2021, then spiked by 107.90% to $81.3 million in 2022, then climbed by 3.91% to $84.5 million in 2023, then dropped by 9.25% to $76.7 million in 2024.
- Its last three reported values are $76.7 million in Q4 2024, $84.5 million for Q4 2023, and $81.3 million during Q4 2022.
